Mayne Pharma launches one more generic oral contraceptive

Tom Smith

&#13 ADELAIDE, Australia, March 4, 2021 /PRNewswire/ — Mayne Pharma Team Confined (ASX: MYX) is happy to announce the industrial start of a generic model of ORTHO-CEPT® (desogestrel and ethinyl estradiol .15 mg / .03 mg) tablets to prospects in the US. &#13 &#13 This is the fourth oral contraceptive launched […]

&#13

ADELAIDE, Australia, March 4, 2021 /PRNewswire/ — Mayne Pharma Team Confined (ASX: MYX) is happy to announce the industrial start of a generic model of ORTHO-CEPT® (desogestrel and ethinyl estradiol .15 mg / .03 mg) tablets to prospects in the US.

&#13
&#13

This is the fourth oral contraceptive launched this calendar calendar year just after launching generic versions of LOESTRIN® 24 FE, ORTHO CYCLEN® and ORTHO TRI-CYCLEN®. According to IQVIA, the annual US current market profits for the four merchandise were being somewhere around US$315 million in the twelve months ending January 2021[1].

&#13
&#13

Mayne Pharma’s CEO Scott Richards stated, “We are extremely delighted to expand our Women’s Wellbeing portfolio which now handles ~80% of Obstetrician/Gynaecologist oral contraceptive prescription volumes[1] and contains 24 promoted branded generic contraceptives. Mayne Pharma is committed to helping meet up with the wants of ladies in the US by supplying price tag effective, higher-good quality and novel contraceptive options. The four new products introduced this year ended up sourced from the strategic partnership with Novast Laboratories.”

&#13
&#13

“In addition, Mayne Pharma has 4 women’s wellbeing pipeline solutions pending at the Food and drug administration which include the novel mixed oral contraceptive NEXTSTELLIS™ (E4/DRSP) and a generic edition of NUVARING®. NEXTSTELLIS which has a Fda concentrate on motion date in April consists of a new estrogen called estetrol or E4 in combination with a progestin, drospirenone. If accredited, E4 will be the 1st new estrogen released in the US for contraceptive use in about 50 years.”

&#13
&#13

About Mayne Pharma

&#13
&#13

Mayne Pharma is an ASX-shown specialty pharmaceutical organization targeted on making use of its drug delivery know-how to commercialise branded and generic prescription drugs, featuring individuals far better and much more obtainable medicines. Mayne Pharma also delivers contract advancement and producing services to far more than 100 customers around the globe.

&#13
&#13

Mayne Pharma has a 40-calendar year observe document of innovation and accomplishment in establishing new oral drug shipping and delivery devices and these technologies have been successfully commercialised in various products and solutions that continue to be marketed about the planet.

&#13
&#13

Mayne Pharma has two facilities centered in Salisbury, Australia and Greenville, United states with know-how in the formulation of intricate oral and topical dose types including potent compounds, modified-release products and inadequately soluble compounds.

&#13
&#13

LOESTRIN® 24 FE, NEXTSTELLIS, NUVARING®, ORTHO-CEPT®, ORTHO CYCLEN® and ORTHO TRI-CYCLEN® are registered trademarks of third functions.

&#13
&#13

 

&#13
&#13


 

&#13
&#13

[1] IQVIA, MAT Income and NSP Models for manufacturer and generic equivalents, January 2021

&#13
&#13

 

&#13
&#13

See unique written content:http://www.prnewswire.com/news-releases/mayne-pharma-launches-a different-generic-oral-contraceptive-301241071.html

&#13
&#13

Source Mayne Pharma

&#13

Next Post

Dance Overview: Structural Dependency by Brooke Leeder (Perth Pageant)

&#13 An industrial, abstract dance get the job done surprises with its personal human touch.&#13 &#13 Structural Dependency by Brooke Leeder & Dancers at Perth Pageant 2021. Photo by Mitchell Aldridge. &#13 &#13 Jo Pickup&#13 &#13 Monday 8 March, 2021&#13 We enter a awesome, expansive studio area and choose our […]

Subscribe US Now